About rRNA methyltransferase 2, mitochondrial
rRNA methyltransferase 2, mitochondrial (MRM2) is a protein
from Homo sapiens identified by UniProt accession
Q9UI43, 246 residues long.
MolForge cross-references it against 0 known binders and
108 disease associations.
Target properties
| Protein name | rRNA methyltransferase 2, mitochondrial |
|---|
| UniProt accession | Q9UI43 |
|---|
| Gene | MRM2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 246 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (108)
Diseases linked to this target (Open Targets).
- mitochondrial DNA depletion syndrome · score 0.45
- neuroblastoma · score 0.15
- mathematical ability · score 0.12
- self reported educational attainment · score 0.12
- plasminogen activator inhibitor 1 measurement · score 0.08
- adolescent idiopathic scoliosis · score 0.08
- age-related macular degeneration · score 0.08
- X-linked retinal dysplasia · score 0.08
- Familial exudative vitreoretinopathy · score 0.07
- severe early-childhood-onset retinal dystrophy · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UI43-F1 | alphafold | PREDICTED | 88.33 | — |
Amino-acid sequence (246 residues)
MAGYLKLVCV SFQRQGFHTV GSRCKNRTGA EHLWLTRHLR DPFVKAAKVE SYRCRSAFKL LEVNERHQIL RPGLRVLDCG AAPGAWSQVA VQKVNAAGTD PSSPVGFVLG VDLLHIFPLE GATFLCPADV TDPRTSQRIL EVLPGRRADV ILSDMAPNAT GFRDLDHDRL ISLCLTLLSV TPDILQPGGT FLCKTWAGSQ SRRLQRRLTE EFQNVRIIKP EASRKESSEV YFLATQYHGR KGTVKQ
Explore rRNA methyltransferase 2, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets